Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark inks agreement SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Posted On: 2021-08-02 03:29:10 (Time Zone: UTC)


Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company and Canadian biotech firm SaNOtize Research & Development Corp. today announced an exclusive long term strategic partnership to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.

In March 2021, SaNOtize's clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms. In the first 24 hours, NONS reduced the average viral load by around 95%, and then by more than 99% within 72 hours. It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.

Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nano-molecule with proven anti-microbial properties, and which has a direct effect on SARS-CoV-2, the virus causing COVID-19.

In early July 2021, Glenmark presented a proposal to the Subject Expert Committee of CDSCO for emergency approval for import and marketing of the nasal spray. The committee has recommended a Phase III clinical trial to be conducted in Indian patients in the weeks to follow. The Phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand name FabiSpray® in India, by fourth quarter of the calendar year 2021.

"Our efforts since the beginning of COVID-19 have been to provide patients with safe and effective treatment options to fight the disease. This partnership with SaNOtize closely aligns with Glenmark's focused approach against COVID-19 and will help reduce the burden of the pandemic in the region." said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd. He further added, "It also marks another valuable in-licensing opportunity for us in our key therapy area of respiratory medicine, as well as the possibility to globally supply the product to SaNOtize and its partners outside of our territory. Glenmark will ensure timely and widespread access to this effective nasal spray, which we hope will bring much needed relief to patients across the region and the wider world."

"COVID-19 and its various variants are proving to be a challenge to contain despite the rapid - and critical - development of vaccines," said Dr. Gilly Regev, CEO & Co-founder of SaNOtize. "SaNOtize is excited to collaborate with Glenmark in providing broader, easier and affordable access to its treatment. In joining forces with Glenmark, SaNOtize can accelerate the efforts to have its antiviral nasal spray available as a self-administered, first line of defence against COVID-19 during the current pandemic and to help prevent future outbreaks."

NONS is one of the few novel therapeutic treatments, outside of expensive monoclonal antibodies, that is proven to reduce SARS-CoV-2 viral load in humans.2 NONS has already received a CE mark in Europe, which is an equivalent of marketing authorization in case of a Medical Device (CE mark confirms that the medical device meets certain "essential requirements" of the European General Medical Devices Directive and is safe for the intended purpose). By virtue of the CE mark, SaNOtize has permission to launch NONS in the EU. NONS is also approved and being sold in Israel and Bahrain, under the name enovid™.

SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections in 2017. Glenmark's partnership with SaNOtize will bring in much needed therapeutic relief to patients in India and Asia.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs. 607.6 as compared to the previous close of Rs. 591.6. The total number of shares traded during the day was 120207 in over 4308 trades.

The stock hit an intraday high of Rs. 611.65 and intraday low of 590.7. The net turnover during the day was Rs. 72429104.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

InterGlobe Aviation Ltd updates on arbitral award

B N Rathi Securities Limited board approves rights issue

Orient Cement Ltd to explore setting up of Cement Grinding Unit at Tiroda, Maharashtra

NBCC India Ltd secures work order at Hulhumale, Maldives

Dalmia Cement Bharat Ltd commences commercial production of Line 2 at its Kapilas Cement Manufacturing Works, Cuttack

Century Plyboards India Ltd increases stake in Century Infotech Ltd to 99.99%

Nucleus Software Exports Limited board approves buy back at Rs. 700 per share

NHPC Ltd to form subsidiary

EKI Energy Services Ltd opens 3 new International Business Points

SJVN bags 1000 MW Solar PV Power Project

Sun TV Network Ltd announces resignation of Mr. J Ravindran

Modern Steels Ltd announces disruption at its plant

Trimurthi Ltd gets Rs. 25 lakhs claim from defaulted broker

Sanrhea Technical Textiles Ltd board to consider preferential issue on Sep 30, 2021

Indiabulls Housing Finance Ltd raises ₹ 251 crores by selling part of its stake in OakNorth Holdings Ltd

Xelpmoc Design and Tech Ltd has sold its stake in Madworks Ventures Pvt Ltd

TPL Plastech Ltd allots 78,00,300 Equity Shares

Unison Metals Ltd to invest in Chandanpani Pvt Ltd

JSW Energy Limited's JV updates on rating

Axis Bank Ltd board to approve Q2, H1FY22 results on Oct 26, 2021

Shree Rama Newsprint Ltd to resume paper division production from Sep 27, 2021

Ramkrishna Forgings Ltd wins yet another Export order worth INR 300 Million per annum from North America in Oil & Gas segment

Huhtamaki India Ltd announces resignation of MD

Trident Sends Gift Vouchers to over 8.25 Lakhs Shareholders, this Festive Season

Cadila Healthcare Limited enters into an agreement with Shilpa Medicare Limited for the production of ZyCoV-D vaccine

ICICI Bank Ltd board to consider Q2FY22, H1FY22 results on Oct 23, 2021

IIFL Finance to raise up to Rs. 1,000 crore via secured NCDs, offers up to 8.75% yield

ANG Lifesciences India Ltd allots 51,83,315 shares

Shilpa Medicare Limited ties up with Cadila Healthcare Ltd for production of ZyCoV-D vaccine

Gayatri Projects Ltd wins arbitration for expressway in Hyderabad City

Caplin Point Laboratories's CRO Amaris Clinicals completes USFDA audit with zero observations

PSP Projects Ltd bags orders worth Rs. 421.87 crores

Ircon International Ltd wins bid to set up 500 MW solar power plant

Zydus Cadila receives final approval from USFDA for Apremilast Tablets

Aurionpro unveils 'AuroPay', a payment platform offering wide range of services in payment domain

CRISIL upgrades rating of Minda Corporation Ltd

Affle India Ltd gets shareholders approval for stock split

Indiabulls Housing Finance Limited has repaid ₹ 7,075.84 Crores of NCDs to investors in September 2021

MoD promulgates framework for increased utilisation of simulators by the three Services & Indian Coast Guard

Kaya Ltd appoints Mr. Rajiv Suri as Global CEO

Suumaya Corporation Ltd announces bonus in the ratio of 2:1

GR Infraprojects Ltd receives LoA for new project

Forbes Asia names Persistent to its 'Best Under A Billion' 2021 List

Aditya Birla Capital Ltd updates on IPO of Aditya Birla Sun Life AMC Ltd

ICRA upgrades rating of Windlas Biotech Limited

Vedanta Limited to delist ADS from NYSE

Dilip Buildcon Limited appointed as mine developer through SC order

Karur Vysya Bank revises base rate, BPLR from Sep 24, 2021

Hero MotoCorp updates on welfare package for Covid-19 families in Rajasthan

Ashoka Buildcon Ltd acquires 60% stake in Ashoka Bettadahalli Shivamogga Road Private Limited


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020